← Leaderboards
Alice Berger
Dana-Farber Cancer Inst
$5,749,854
Attributed
$6,441,094
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2015–25$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,441,094 · 7
By mechanism
R37$2,653,338 · 1
R01$2,494,212 · 2
R00$747,000 · 1
P50$390,808 · 2
K99$155,736 · 1
Top collaborators
- Angela Norie Brooks2 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Ulrike S Eggert$2,581,362
- David S Pellman$18,057,380
- Xiaole Shirley Liu$12,534,646
- Shannan J Ho Sui$927,996
- Luca Pinello$6,835,504
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMutationTumorigenesisMalignant NeoplasmsMalignant Neoplasm Of LungCellsTargeted TreatmentGenomicsGeneticLung AdenocarcinomaEventLung NeoplasmsCancer Cell LineKras2 GeneMutantBiologicalMutateLungMapsLaboratoriesMediatingFunctional GenomicsGain Of Function MutationCancer Therapy
Grant awards (20)
Computational and functional discovery of isoforms driving cancer and drug resistance$684,945
R01 · FY2025 · CA
Expanding the cancer paralog genetic interaction map to enable precision oncology$548,562
R01 · FY2025 · CA · contact PI
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer$467,377
R37 · FY2025 · CA · contact PI
Career Enhancement Program$308,965
P50 · FY2025 · CA · contact PI
Computational and functional discovery of isoforms driving cancer and drug resistance$697,535
R01 · FY2024 · CA
Expanding the cancer paralog genetic interaction map to enable precision oncology$563,170
R01 · FY2024 · CA · contact PI
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer$444,008
R37 · FY2024 · CA · contact PI
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer$129,789
R37 · FY2024 · CA · contact PI
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer$5,840
R37 · FY2024 · CA · contact PI
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer$458,029
R37 · FY2023 · CA · contact PI
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer$135,696
R37 · FY2023 · CA · contact PI
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer$77,845
R37 · FY2023 · CA · contact PI
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer$467,377
R37 · FY2022 · CA · contact PI
Career Enhancement Program$81,843
P50 · FY2022 · CA · contact PI
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer$467,377
R37 · FY2021 · CA · contact PI
Investigating the role of the small GTPase RIT1 in lung adenocarcinoma$249,000
R00 · FY2019 · CA · contact PI
Investigating the role of the small GTPase RIT1 in lung adenocarcinoma$249,000
R00 · FY2018 · CA · contact PI
Investigating the role of the small GTPase RIT1 in lung adenocarcinoma$249,000
R00 · FY2017 · CA · contact PI
Investigating the role of the small GTPase RIT1 in lung adenocarcinoma$22,628
K99 · FY2016 · CA · contact PI
Investigating the role of the small GTPase RIT1 in lung adenocarcinoma$133,108
K99 · FY2015 · CA · contact PI